Geom Therapeutics
San Francisco
About Geom Therapeutics
Geom Therapeutics is a biotechnology company focused on the development of novel antibiotics for multidrug-resistant Gram-negative infections. Geom is a joint venture with LegoChem Biosciences, a publicly traded Korean biotechnology company (KOSDAQ:141080) and the inventor of GT-1. GT-1, their lead product candidate, a cephalosporin with a novel uptake mechanism, has demonstrated broad spectrum efficacy against Gram-negative pathogens. They are developing GT-1 for serious bacterial infections, including those caused by MDR P. aeruginosa and Acinetobacter spp. They have built an exceptional research and development team with deep expertise in the development of new antibiotics from discovery through approval. Their mission is to improve patients’ lives by developing novel antibiotics to treat resistant infections for which there are no available therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $4.4M
- Last round: Series Unknown (Apr 2017)
- Website: geomtherapeutics.com
- Phone: 415-533-3236
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/geom-therapeutics-94442 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.